SCYNEXIS, Inc.
$0.67+1.67%(+$0.01)
TickerSpark Score
68/100
84
Valuation
40
Profitability
100
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCYX research report →
52-Week Range14% of range
Low $0.56
Current $0.67
High $1.31
Companywww.scynexis.com
SCYNEXIS, Inc. , a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC).
- CEO
- David Gonzalez Angulo
- IPO
- 2014
- Employees
- 28
- HQ
- Jersey City, NJ, US
Price Chart
-16.46% · this period
Valuation
- Market Cap
- $33.63M
- P/E
- -1.39
- P/S
- 1.65
- P/B
- 0.82
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -119.86%
- Net Margin
- -120.51%
- ROE
- -57.16%
- ROIC
- -39.18%
Growth & Income
- Revenue
- $20.60M · 449.95%
- Net Income
- $-8,609,000 · 59.56%
- EPS
- $-0.17 · 61.36%
- Op Income
- $-16,074,000
- FCF YoY
- 78.00%
Performance & Tape
- 52W High
- $1.31
- 52W Low
- $0.56
- 50D MA
- $0.92
- 200D MA
- $0.80
- Beta
- 1.12
- Avg Volume
- 558.94K
Get TickerSpark's AI analysis on SCYX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Angulo Gonzalez David | buy | 108,695 |
| Apr 1, 26 | Angulo Gonzalez David | buy | 108,695 |
| Jan 29, 26 | Macleod ivor | other | 129,833 |
| Jan 29, 26 | Sukenick Scott | other | 129,833 |
| Jan 29, 26 | Angulo Gonzalez David | other | 391,333 |
| Oct 17, 25 | Angulo Gonzalez David | other | 32,500 |
| Jun 26, 25 | Tinmouth Brian Philippe | other | 23,000 |
| Jun 26, 25 | Tinmouth Brian Philippe | other | 23,000 |
| Jun 26, 25 | Macdonald Guy | other | 23,000 |
| Jun 26, 25 | Macdonald Guy | other | 23,000 |
Our SCYX Coverage
We haven't published any research on SCYX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCYX Report →Similar Companies
TLPH-0.94%
Talphera, Inc.
$0.82
COSM+0.64%
Cosmos Health Inc.
$0.28
CVKD+3.82%
Cadrenal Therapeutics, Inc. Common Stock
$5.16
XCUR+3.46%
Exicure, Inc.
$2.99
KLTO-7.10%
Klotho Neurosciences, Inc.
$0.38
CLGN+7.17%
CollPlant Biotechnologies Ltd.
$0.45
SONN-59.35%
Sonnet BioTherapeutics Holdings, Inc.
$1.26
NXL+4.36%
Nexalin Technology, Inc.
$0.34